GH receptor isoforms and skeletal fragility in acromegaly

Marilda Mormando1, Luigi A Nasto2, Antonio Bianchi1, Gherardo Mazziotti3, Antonella Giampietro1, Enrico Pola2, Alfredo Pontecorvi1, Andrea Giustina3 and Laura De Marinis1

1Pituitary Unit, Department of Endocrinology and 2Division of Spine Surgery, Department of Orthopaedics and Traumatology, Catholic University School of Medicine, ‘A. Gemelli’ University Hospital, I-go Agostino Gemelli 8, 00168 Rome, Italy and 3Chair of Endocrinology, University of Brescia, 25125 Brescia, Italy

Abstract

Objective: Acromegaly is associated with an increased prevalence of vertebral fractures (VFs) in close relationship with GH hypersecretion. Two isoforms of the GH receptor (GHR) have been identified; the two isoforms differ or not by the expression of the protein fragment encoded by exon 3 of the GHR gene. Deletion of the exon 3 may influence the functional properties of the GHR and affect fracture risk in acromegalic patients.

Design: A cross-sectional study was designed to investigate the association between the d3-GHR isoform and the prevalence of VFs in patients with acromegaly.

Methods: In this study, 109 acromegalic patients were included (M/F, 48/61): 73 with controlled/cured acromegaly and 36 with active disease. GHR genotype was assessed in each patient. All patients were evaluated for VFs and bone mineral density at lumbar spine and hip. Serum IGF1 levels and bone metabolism markers were measured. A multivariate analysis was performed to establish risk factors for VFs in our population.

Results: d3-GHR carriers showed an increased prevalence of VFs when compared with patients expressing full-length GHR (35/55 vs 12/54; \( P<0.001 \)). The association between GHR deletion and VFs was demonstrated both in patients with active disease and in those with controlled/cured disease. Out of 35 patients who were prospectively evaluated, 13 (37.1%) developed incident VFs. The incidence of VFs was significantly higher in patients for whom the GHR gene has been deleted when compared with those harboring the fl gene (\( P=0.04 \)). In multivariate analysis, male sex (odds ratio (OR), 3.250; \( P=0.041 \)), IGF1 levels (OR, 1.183; \( P=0.031 \)), length of active diseases (OR, 1.038; \( P=0.001 \)), and d3-GHR genotype (OR, 3.060; \( P=0.015 \)) were all confirmed as risk factors of VFs in our population.

Conclusions: This study suggests for the first time that exon 3 deletion of GHR may predispose patients with active and controlled acromegaly to a higher risk of VFs.

Introduction

Growth hormone (GH) and insulin-like growth factor 1 (IGF1) are important regulators of the bone remodeling process. Although GH may act directly on skeletal cells, most of its effects are mediated by IGF1 that exerts its action as a systemic hormone synthesized in the liver under GH stimulation or as a local growth factor synthesized in peripheral tissues (1). Circulating GH binds to a single-chain transmembrane glycoprotein receptor (GH receptor (GHR)). The GHR in its final form consists of an extracellular, a transmembrane, and an intracellular domain, whereas the GHR gene consists of nine exons encoding the receptor protein and several additional untranslated exons (2). To date, two isoforms of human GHR have been identified: a full-length (fl-GHR) isofom retaining the protein fragment encoded by exon 3 and an exon 3-deficient (d3-GHR) isoform excluding this
GHR on bone metabolism, bone mineral density (BMD), our study is to investigate the effects of exon 3 deletion of polymorphisms on skeletal fragility. Therefore, the aim of a better model to study the potential impact of GHR gly. In our opinion, active acromegaly may well provide analysis to patients with longstanding controlled acromegaly. Recently, Wassenaar et al. did not find any significant association between the deletion of GHR exon 3 and VFs. However, the authors restricted their analysis to patients with longstanding controlled acromegaly. In our opinion, active acromegaly may well provide a better model to study the potential impact of GHR polymorphisms on skeletal fragility. Therefore, the aim of our study is to investigate the effects of exon 3 deletion of GHR on bone metabolism, bone mineral density (BMD), and incidence of VFs in patients with active and controlled/cured acromegaly.

Subjects and methods

Subjects

A cross-sectional study was designed and a total of 109 patients consecutively treated at our Institution (Pituitary Unit of Endocrinology Department, Gemelli Hospital, Rome) were enrolled. All patients were diagnosed with acromegaly or had a previous diagnosis of acromegaly. Exclusion criteria from the study were: i) diagnosis of active neoplastic disease; ii) ongoing treatment with anti-osteoporotic drugs with the exception of calcium and vitamin D supplements; iii) treatment with drugs causing osteoporosis with the exception of glucocorticoid replacement therapy in hypopituitary patients; iv) clear history of moderate or high-energy VFs; v) history of surgical intervention on the spine; and vi) prolonged immobilization (more than 6 weeks). Out of the 109 enrolled patients, 84 had been already evaluated in previously published studies from our research group. Both surgically treated and medically treated patients were included.

Active acromegaly was defined as the failure of suppression of GH plasma levels ≤1 ng/ml after a 75 g oral glucose load and fasting plasma IGF1 levels above the normal ranges for sex and age. Patients undergoing somatostatin analog treatment were evaluated by measurement of serum random GH and IGF1, and those undergoing pegvisomant were evaluated by serum IGF1 alone, whereas patients treated by neurosurgery alone were evaluated also by serum GH after a 75 g oral glucose load, according to the current guidelines. Acromegaly was defined as controlled if the IGF1 values were within the reference ranges for age and, in patients undergoing treatment with somatostatin analogs and after neurosurgery, random GH was below 1.0 ng/ml. When the 75 g oral glucose load was performed, the GH values of 0.4 ng/ml or below were considered as expression of cured disease. Disease activity was defined as ‘cured’ if, after a previous treatment for acromegaly, patients had normal biochemical parameters at follow-up with no ongoing medical therapy. Patients’ gonadal status was also assessed: hypogonadism was defined as absence of or irregular menstrual cycles in women and low total testosterone associated with symptoms and signs of sexual dysfunction in men. Hypogonadic patients undergoing replacement therapy with sex steroids were assumed to be eugonadal only if treatment was started at least 12 months before study entry. All patients signed an informed consent form after full explanation of the purpose and nature of all procedures used. The study was also approved by our Institutional Ethical Committee.

Biochemical measurements

All biochemical measurements were performed within 6 months of lumbar and femoral neck dual energy X-ray absorptiometry (DXA) scan and vertebral X-ray assessment. Blood samples were collected in fasting conditions. GH and IGF1 levels were measured using the Immulite 2000 immunoassay system (Siemens, Diagnostic Product Corp., Los Angeles, CA, USA). The inter-assay coefficient of variation was 5.5–6.2% for GH assay, and 6.4–11.5% for IGF1 assay; detection lower limits were 0.01 and 0.2 μg/l.
respectively. IGF1 levels were reported as absolute concentrations and SDS relative to normal age-adjusted adult values (normal range from -2 to +2 SDS). The formula used for SDS calculation is, as reported previously, \( (\text{IGF1}_{\text{p}} - \text{IGF1}_{\text{adj-value}})/\text{IGF1}_{\text{S.D.}} \), where IGF1_{\text{p}} is the absolute level of IGF1 of the patient, and IGF1_{\text{adj-value}} and IGF1_{\text{S.D.}} are the average and the S.D. of the age-matched IGF1 levels in healthy patients respectively (19). Serum 25-hydroxy vitamin D was measured using a chemiluminescent assay (Liaison Instrument, DiaSorin Inc, Stillwater, MN, USA), reference intervals for the study were <10 ng/ml for severe deficiency, 10–30 ng/ml for mild to moderate deficiency, and 31–100 ng/ml for normal status. Serum parathyroid hormone levels were measured using an immunoenzymatic method (reference interval, 0.2–1.0 ng/ml).

**IGF1S.D.** are the average and the S.D. of the age-matched levels of IGF1 of the patient, and IGF1 adj-value and IGF1 S.D. are calculated for each patient. Each VF was assigned a score according to the fracture severity (one for mild, two for moderate, and three for severe); SDI was defined as the sum of all scores in a single patient (22).

After 3 years of follow-up, 35 patients without pre-existing VFs were evaluated for incident VFs. Incident VFs were defined as a decrease of 20% or more and at least 4 mm in length in any of the three vertebral heights (Ha, Hm, or Hp) compared with baseline radiograph (16).

**Genetic testing**

DNA was extracted from 100–200μl peripheral blood using the Illustra blood genomicPrep Mini Spin Kit (GE Healthcare, Little Chalfont, UK) for the detection of the GHR gene polymorphism. Polymorphisms were studied through standard PCR amplification by Eppendorf Master Mix (2.5X) (Eppendorf, Hamburg, Germany). The following primers were used for amplification, 5’-TGTGCTGGTCTGTTGGTCTG-3’, 5’-AGTCGGTCC-TGGGACGAGA-3’, and 5’-CCTGGATTAACACTTTTGCAGACT-3’ (23). The reaction was carried out with one cycle at 94°C for 5 min (denaturing), 35 cycles at 94°C for 30 s (denaturing), 60°C for 30 s (annealing), 72°C for 60 s (extension), and one cycle at 72°C for 7 min (last extension). The amplification products were separated by electrophoresis on 2% agarose gel and visualized by ethidium bromide labeling. The full-length allele (fl-GHR) is represented by a 935-bp fragment and the exon 3-deficient allele (d3-GHR) by a 532-bp fragment.

**Statistical analysis**

Data are expressed as mean ± s.d., unless otherwise stated. Continuous variables were tested using the t-test, whereas frequencies were compared using the χ2-test with the Fisher correction, when appropriate. Correlation between variables was sought using Pearson’s correlation coefficient. A multivariate logistic regression model was used for statistical analysis of risk factors for occurrence of VFs. Statistical significance was assumed when \( P \leq 0.05 \). Data were analyzed using the SPSS Software, version 17.

**Results**

A total of 48 men and 61 women were included in the study (mean age 47 years, ±19–79). Of them, 58 patients had controlled disease (nine of them received medical therapy as first-line treatment, whereas 49 were treated with somatostatin analogs or pegvisomant after unsuccessful neurosurgery) and 15 patients were cured by neurosurgery. The remaining 36 patients had active disease; of them, 31 were on medical therapy after unsuccessful neurosurgery and radiotherapy and five were waiting for surgery or refused it at the time of this study. Of the total number of patients, 61 patients were eugonadal (35 men and 26 women), 20 patients were...
hypogonadal (13 men and seven women), and the remaining 28 women were post-menopausal and were assigned to the hypogonadic group as well.

We found 54 patients (49.5%) to be homozygous for the fl-GHR isoform and 55 patients (50.5%) to be carriers of at least one allele of the d3-GHR isoform. A total of 18 patients were homozygous for the d3-GHR isoform. Patients were assigned to two groups: i) homozygous carriers of the WT allele (flfl-GHR, referred as fl patients hereafter) and ii) homozygous or heterozygous carriers of the exon 3-deficient allele (fld3-GHR and d3d3-GHR, referred as d3 patients hereafter). We decided to apply a dominant model because we did not observe any significant difference in terms of VFs between carriers of one d3 allele and carriers of two d3 alleles; we did not observe any gene-dosage effect on fractures. The two groups did not differ in sex, lumbar BMD values, serum IGF1 levels, and bone metabolism parameters (PTH, vitamin D, osteocalcin, and β-CTX). BMD and Z-score of the lumbar spine were not different between fl patients and d3 patients even after adjusting values for gender and BMI (Table 1). A significantly positive linear correlation between IGF1–SDS levels and vitamin D, osteocalcin, and PTH (β-CTX). BMD and Z-score of the lumbar spine were not different between fl patients and d3 patients even after adjusting values for gender and BMI (Table 1). A significantly positive linear correlation between IGF1–SDS levels and vitamin D, osteocalcin, and PTH (β-CTX). BMD and Z-score of the lumbar spine were not different between fl patients and d3 patients even after adjusting values for gender and BMI (Table 1). A significantly positive linear correlation between IGF1–SDS levels and vitamin D, osteocalcin, and PTH (β-CTX). BMD and Z-score of the lumbar spine were not different between fl patients and d3 patients even after adjusting values for gender and BMI (Table 1).

Of the total number of patients, 47 (43.1%) had at least one VF, with a total of 53 mild, 13 moderate, and eight severe fractures. The average SDI of fractured patients was 2.19 (±1.48). Fractured patients did not differ from non-fractured patients with regard to age (48.49 vs 45.32 years, P=0.213), lumbar Z-score (−0.57 vs −0.10, P=0.100), femoral Z-score (0.153 vs 0.280, P=0.527), and duration of total disease (91.43 vs 72.17 months, P=0.151). Patients with fractures were more frequently male (27/47 males, 57.4% vs 21/62 females, 33.8%) (P=0.012). Moreover, fractured patients showed significantly higher IGF1 levels (SDS 3.45 vs 2.10; P=0.022), and had longer duration of active disease (52.43 vs 23.31 months; P<0.001) than non-fractured patients. PTH and vitamin D levels did not differ significantly between the two groups. Osteocalcin levels did not differ significantly either (P=0.769), whereas β-CTX levels were higher in fractured patients although not significantly so (0.61 vs 0.45 ng/ml; P=0.071) (Table 2).

Prevalence of VFs was significantly higher in d3 carriers than fl patients (63.6 vs 22.2%; P<0.001) and this association was confirmed in patients with controlled/cured and active disease (Fig. 2). The mean SDI was significantly higher in fractured d3 carriers (1.24±1.44)

---

**Table 1** Baseline characteristics of the two populations of the study (flfl-GHR carriers vs fld3/d3d3-GHR carriers).

<table>
<thead>
<tr>
<th>Variables</th>
<th>flfl (n=54)</th>
<th>fld3/d3d3 (n=55)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>46.52 (±14.21)</td>
<td>46.85 (±12.06)</td>
<td>0.894</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>54 (23/31)</td>
<td>55 (25/30)</td>
<td>0.457</td>
</tr>
<tr>
<td>Length of disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total (months)</td>
<td>83.87 (±68.63)</td>
<td>77.44 (±69.37)</td>
<td>0.631</td>
</tr>
<tr>
<td>Active (months)</td>
<td>38.79 (±41.40)</td>
<td>33.86 (±36.52)</td>
<td>0.531</td>
</tr>
<tr>
<td>Disease status</td>
<td>20 active, 28 controlled, and six healed</td>
<td>16 active, 29 controlled, and ten healed</td>
<td>0.484</td>
</tr>
<tr>
<td>Lumbar BMD</td>
<td>1.165 (±0.168)</td>
<td>1.113 (±0.163)</td>
<td>0.146</td>
</tr>
<tr>
<td>Lumbar Z-score</td>
<td>−1.132 (±1.328)</td>
<td>−0.468 (±1.287)</td>
<td>0.240</td>
</tr>
<tr>
<td>Femoral neck BMD</td>
<td>1.036 (±0.212)</td>
<td>0.980 (±0.143)</td>
<td>0.141</td>
</tr>
<tr>
<td>Femoral neck Z-score</td>
<td>0.288 (±0.948)</td>
<td>0.154 (±0.893)</td>
<td>0.503</td>
</tr>
<tr>
<td>IGF1 (SDS)</td>
<td>3.13 (±3.35)</td>
<td>2.65 (±2.97)</td>
<td>0.382</td>
</tr>
<tr>
<td>PTH (pg/ml)</td>
<td>51.33 (±26.92)</td>
<td>54.51 (±39.10)</td>
<td>0.631</td>
</tr>
<tr>
<td>Vitamin D (ng/ml)</td>
<td>15.80 (±11.03)</td>
<td>15.66 (±11.07)</td>
<td>0.951</td>
</tr>
<tr>
<td>Osteocalcin (ng/ml)</td>
<td>22.48 (±12.50)</td>
<td>27.67 (±25.09)</td>
<td>0.322</td>
</tr>
<tr>
<td>Crosslaps (ng/ml)</td>
<td>0.57 (±0.41)</td>
<td>0.62 (±0.41)</td>
<td>0.616</td>
</tr>
<tr>
<td>No. of fractured patients (%)</td>
<td>12/54 (22%)</td>
<td>35/55 (63%) &lt;0.001</td>
<td></td>
</tr>
<tr>
<td>No. of fractures</td>
<td>19 (nine mild, four moderate, and six severe)</td>
<td>55 (44 mild, nine moderate, and two severe)</td>
<td></td>
</tr>
<tr>
<td>Fractures/patient</td>
<td>0.35 (±0.70)</td>
<td>1.00 (±1.00)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>SDI</td>
<td>0.65 (±1.43)</td>
<td>1.24 (±1.44)</td>
<td>0.035</td>
</tr>
</tbody>
</table>

SDI, spinal deformity index.
than in fractured fl carriers (0.65 ± 1.43) (P = 0.035). In 35 patients prospectively evaluated, 13 (37.1%) developed incident VFs. The incidence of VFs was significantly higher in patients for whom the GHR gene has been deleted when compared with those harboring the fl gene (52.6 vs 18.8%; χ², 4.3; P = 0.04).

**Multivariate analysis**

Variables associated with VFs were entered in a multivariate logistic regression model in order to assess the fracture risk associated with each variable. GHR isoform, IGF1 levels, length of active disease, and male sex were all significantly associated with an increased risk of VFs. Odds ratio (OR) of having a VF in patients who were carriers of one or two d3 alleles was 3.060 (P = 0.015). Each 1 SDS level of IGF1 was associated with a 1.183 OR (P = 0.031), whereas length of active disease each month had 1.038 OR (P = 0.001). Male sex was associated with an increased risk of VFs with an OR of 3.250 (P = 0.041; Table 3).

**Discussion**

Data from our study demonstrate for the first time, to the best of our knowledge, that the deletion of the exon 3 of GHR (d3-GHR) in at least one allele is associated with a higher prevalence of VFs in acromegalic patients. This is the first report examining the effects of GHR isoforms on bone fragility and risk of VFs in a heterogeneous population of patients (active acromegaly, controlled/cured disease).

The d3-GHR polymorphism enhances GHR signal transduction by altering the structure of the extracellular domain of the receptor. The increased intracellular signal transduction may enhance sensitivity to GH as demonstrated by studies conducted on GH-deficient children.

**Table 2** Baseline characteristics of the two populations of the study (fractured patients vs patients without fractures).

<table>
<thead>
<tr>
<th>Variables</th>
<th>Fractured (n=47)</th>
<th>Non-fractured (n=62)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>48.49 (± 14.48)</td>
<td>45.32 (± 11.91)</td>
<td>0.213</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>27/20</td>
<td>21/41</td>
<td>0.012</td>
</tr>
<tr>
<td>Lumbar BMD (g/cm²)</td>
<td>1.112 (± 0.165)</td>
<td>1.158 (± 0.167)</td>
<td>0.210</td>
</tr>
<tr>
<td>Lumbar Z-score (SDS)</td>
<td>−0.57 (± 1.374)</td>
<td>−0.10 (± 1.230)</td>
<td>0.100</td>
</tr>
<tr>
<td>Femoral BMD (g/cm²)</td>
<td>1.007 (± 0.170)</td>
<td>1.008 (± 0.193)</td>
<td>0.980</td>
</tr>
<tr>
<td>Femoral Z-score (SDS)</td>
<td>0.153 (± 0.801)</td>
<td>0.280 (± 1.017)</td>
<td>0.527</td>
</tr>
<tr>
<td>IGF1–SDS (g/L)</td>
<td>3.45 (± 3.52)</td>
<td>2.10 (± 2.29)</td>
<td>0.022</td>
</tr>
<tr>
<td>Length of disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total (months)</td>
<td>91.43 (± 77.38)</td>
<td>72.17 (± 60.49)</td>
<td>0.151</td>
</tr>
<tr>
<td>Active (months)</td>
<td>52.43 (± 47.46)</td>
<td>23.31 (± 23.67)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>PTH (pg/ml)</td>
<td>57.20 (± 46.63)</td>
<td>49.66 (± 17.72)</td>
<td>0.256</td>
</tr>
<tr>
<td>Vitamin D (ng/ml)</td>
<td>14.97 (± 11.39)</td>
<td>16.33 (± 10.74)</td>
<td>0.540</td>
</tr>
<tr>
<td>Osteocalcin (ng/ml)</td>
<td>20.61 (± 8.96)</td>
<td>19.82 (± 8.96)</td>
<td>0.769</td>
</tr>
<tr>
<td>Crosslaps (ng/ml)</td>
<td>0.61 (± 0.36)</td>
<td>0.45 (± 0.21)</td>
<td>0.071</td>
</tr>
<tr>
<td>Gonadal status</td>
<td>ipogon/23 no ipogon</td>
<td>24 ipogon/38 no ipogon</td>
<td>0.137</td>
</tr>
<tr>
<td>GHR polymorphism</td>
<td>12 flfl/35 d3</td>
<td>42 flfl/20 d3</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

ipogon, hypogonadic.
treated with recombinant human GH. Patients expressing d3-GHR have an increased growth velocity and eventually they reach a higher final height (6, 7). On the other hand, d3-GHR polymorphism confers higher susceptibility to GH stimulation in acromegalic patients and may negatively affect phenotypic presentation and long-term complications of the disease. Nonetheless, the effect of d3-GHR polymorphism on GH/IGF1 levels is controversial. Mercado et al. (24) reported a significant correlation between IGF1 and GH levels only in d3-GHR carriers. Bianchi et al. (9) demonstrated that basal GH vs IGF1 relationship was discordant in d3 carriers, but it became concordant (GH normal and IGF1 increased) after neurosurgery or somatostatin analog treatment, thus suggesting that small differences in GHR isoforms sensitivity exist and are possible although these differences could not be immediately evident in active acromegaly because of the elevated levels of circulating GH. At the time of our study, there were no differences observed in terms of IGF1 levels between fl-GHR and d3-GHR carriers, although we did not measure GH levels because of the confounding effect of some therapies (pegvisomant) on this assessment.

In this study, we focused our attention on bone phenotype of acromegalic patients and particularly on the prevalence of VFs. With regard to the impact of GHR isoforms on complications of acromegaly, Montefusco et al. (25) found that patients carrying at least one d3 allele had a lower BMI, normal glucose tolerance, and lower insulin levels 120 min after an oral glucose load than patients homozygous for fl-GHR; these data suggest that GHR polymorphism may well affect the weight and metabolic phenotype. Wassenaar et al. (13) investigated the impact of d3 deletion of GHR on BMD, osteoarthritis, and (non) VFs. The authors also studied the prevalence of other comorbidities such as adenomatous polyps, dolicoocolon, and the association between anthropometric parameters, cardiovascular risk factors, and GHR isoforms. In a selected population of patients with long-term remission of acromegaly, Wassenaar et al. demonstrated that d3 carriers had an increased prevalence of osteoarthritis, adenomatous polyps, and dolicoocolon but anthropometric parameters, cardiovascular risk factors, BMD, and (non) VFs did not differ between fl homozygous patients and d3 patients.

In our population, comprising patients with active and controlled/cured acromegaly, we confirmed some of the previous results concerning BMD not significantly correlated with fractures (14, 15). However, in our cohort, a significant difference in terms of prevalence of VFs was observed between fl homozygous patients and d3 carriers. In fact, patients carrying at least one d3 allele had a significantly increased prevalence of VFs (Fig. 2). Another original observation of our study was concerned with bone metabolism markers and their association with fractures. Previous studies demonstrated that active acromegaly was associated with increased calcium and phosphate serum levels, increased calciuria and markers of bone formation, and bone resorption (26, 27, 28, 29, 30, 31). Bonadonna et al. (14) found that fractured acromegalic women had

**Table 3** Results from a logistic regression analysis of independent variables correlating with fracture risk.

<table>
<thead>
<tr>
<th>Independent variables</th>
<th>OR (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (male)</td>
<td>3.250 (1.051–10.048)</td>
<td>0.041</td>
</tr>
<tr>
<td>d3 genotype</td>
<td>3.060 (0.700–13.381)</td>
<td>0.015</td>
</tr>
<tr>
<td>IGF1–SDS (per SDS)</td>
<td>1.183 (0.951–1.472)</td>
<td>0.031</td>
</tr>
<tr>
<td>Length of active disease (per month)</td>
<td>1.038 (1.016–1.060)</td>
<td>0.001</td>
</tr>
</tbody>
</table>
higher serum bone alkaline phosphatase and urinary deoxypitridinoline and lower serum levels of vitamin D compared with non-fractured patients, but the study population was too small (36 women) to draw any real final conclusion. In our population, β-CTx (a bone catabolism marker) correlated with a higher prevalence of VFs and, although not significant (P=0.07), this assessment may be helpful to estimate bone fragility in acromegalic patients. In addition, we found a positive linear correlation between IGF1–SDS and disease) and linear correlation between IGF1 levels (increased in active acromegalic patients. In addition, we found a positive real final conclusion. In our population, on a mixed population of acromegaly patients (i.e. with active and controlled/cured disease), we did not find a significant association between hypogonadism and VFs. The real novelty of this work is the strong correlation found between d3-GHR isoform and high prevalence of VFs in patients with acromegaly. Interestingly, we also observed a significant correlation between d3-GHR isoform and incident VFs in a small subgroup of acromegalic patients followed up for 3 years. Notably, all these patients did not have a high prevalence of VFs at baseline and this feature provides further evidence that deletion of GHR might have been involved in the pathogenesis of skeletal fragility in acromegaly regardless of coexistent risk factors for fractures (16). Very few contrasting data are currently available on the relationship between GHR polymorphisms and osteoporosis in healthy patients. A progressive decrease in GH secretion has been hypothesized; however, recent experimental evidences have suggested that, besides the age-dependent decline of GH and IGF1 serum levels, dysregulation of GH and IGF1 action may be due to an impairment of the post-receptor signaling of GHR (42). In rodents, complete inhibition of GH action by disrupting or knocking out of the GHR gene (which resulted in GH resistance, elevated GH levels, and markedly reduced IGF1 levels) led to reduced muscle mass and BMD (43). In line with these observations, some authors reported that subjects receiving GH replacement therapy showed no significant changes in BMD (44, 45), probably because of other mechanisms being involved in elderly subjects affected by pituitary disease (i.e. impaired post-receptor GH signaling). The effects of GHR exon 3 isoform expression on osteoporosis has been studied in healthy patients previously. Kenth et al. (46) studied the possible influence of GHR exon 3 isoform on final adult height, quantitative ultrasound (QUS) of the heel, and BMD (spine and femoral neck) in a healthy population of 368 white women; there was no correlation between GHR exon 3 genotype and final height, QUS, and BMD. In acromegalic patients, Waassenar et al. (13) did not find a significant difference in terms of BMD and prevalence of VFs between carriers of exon 3 deletion and patients carrying the WT allele. In our population, on the other hand, which consists also of patients affected by active acromegaly, a stronger impact of GHR polymorphism on the risk of fracture due to GH excess can be expected.
In conclusion, our study demonstrates for the first time that another important risk factor for vertebral fragility fractures in acromegalic patients does exist, i.e. the presence of d3 deletion of GHR gene. Genetic testing may represent an additional tool for stratification of risk of VFIs in acromegalic patients and help in devising an ordered plan and adequate management in each patient.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Author contribution statement
L De Marinis designed this study and M Mormando conducted the study. M Mormando and A Giampietro collected data. L A Nasto, A Bianchi, and G Maziotti conducted data analysis and interpretation. M Mormando drafted the manuscript. L A Nasto, A Giustina, and E Pola revised the manuscript content. A Pontecorvi, E Pola, and L De Marinis approved the final version of the manuscript. L Mormando and L De Marinis were responsible for the integrity of the data.

References
3 Urbanek M, MacLeod JN, Cooke NE & Liehhaber SA. Expression of a human growth hormone (hGH) receptor isoform is predicted by tissue-specific alternative splicing of exon 3 of the hGH receptor gene transcript. *Molecular Endocrinology* 1992 6 279–287. (doi:10.1210/mer.6.2.1569971)
5 Dos Santos C, Essioux L, Teinturier C, Tauber M, Goffin V & Bougnères P. A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. *Nature Genetics* 2004 36 720–724. (doi:10.1038/ng1379)
21 Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D & Cummings SR. Comparison of semiquantitative visual and quantitative...

22 Crans GG, Genant HK & Krieg JH. Prognostic utility of a semiquanti-
bone.2005.04.003)

23 Pantel J, Machinis K, Sobrier ML, Duquesnoy P, Goossens M & 
Amsellem S. Species-specific alternative splice mimicry at the growth 
hormone receptor locus revealed by the lineage of retroelements 
during primate evolution. *Journal of Biological Chemistry* 2000 **275** 
18664–18669. (doi:10.1074/jbc.M001615200)

24 Mercado M, González B, Sandoval C, Esquenazi Y, Mier F, Vargas G, 
2008-0391)

25 Montefusco L, Filopanti M, Ronchi CL, Olgiati L, La-Porta C, Losa M, 
hormone receptor polymorphism in acromegaly: effects on metabolic 
1365-2265.2009.03703.x)

Tita P. Prevalence of osteoporosis and vertebral fractures in acromegalic patients. *Clinical Cases in Mineral and Bone Metabolism* 2011 **8** 37–43.

27 Halse J & Haugen HN. Calcium and phosphate metabolism in 

Sentinel bone Gla protein as a marker of bone turnover in acromegaly. 
*Calcified Tissue International* 1993 **52** 419–421. (doi:10.1007/BF00571329)

29 De la Piedra C, Larrañaga J, Castro N, Horcajada C, Rapado A, Herrera 
Ezzat S, Melmed S, Endres D, Eyre DR & Singer FR. Biochemical 
Ueland T, Fougner SL, Godang K, Schreiner T & Bollerslev V. Serum Gh 

30 Madeira M, Neto LV, de Paula Paranhos Neto F, Barbosa Lima IC, 
Carvalho de Mendonça LM, Gadelha MR & Fleius de Farias ML. Acromegaly has a negative influence on trabecular bone, but not on cortical bone, as assessed by high-resolution peripheral quantitative computed tomography. *Journal of Clinical Endocrinology and Metabolism* 2013 **98** 1734–1741. (doi:10.1210/jc.2012-04073)

31 Gola M, Bonadonna S, Doga M & Giustina A. Clinical review: Growth 
hormone and cardiovascular risk factor. *Journal of Clinical 
2004-0545)


33 Madeira M, Neto LV, de Lima GA, Moreira RO, de Mendonça LM, 
7326/0003-4819-11-7-567)

34 Berrymen DE, Christiansen JS, Johannsson G, Thorner MO & 
Kopchick J. Role of the GH/IGF1 axis in lifespan and healthspan: 

35 Hoffman AR, Kuntze JE, Baptista J, Baum HB, Baumann GP, Biller BM, 
Clark RV, Cook D, Inzucchi SE & Kleinberg D. Growth hormone (GH) 
replacement therapy in adult-onset GH deficiency. Effects on body 
composition in men and women in a double-blind, randomized, 

36 Melmed S, Casanueva FF, Klibanski A, Bromstein MD, Chanson P, 
Lamberts SW, Strasburger CJ, Wass JA & Giustina A. A consensus on the 

37 Mazziotti G, Bilezikian J, Canalis E, Cocchi D & Giustina A. New under 
standing and treatments for osteoporosis. *Endocrine* 2012 **41** 58–69. (doi:10.1210/jcem2012-0119570-2)

38 Gola M, Bonadonna S, Doga M & Giustina A. Clinical review: Growth 
hormone and cardiovascular risk factor. *Journal of Clinical 
2004-0545)

39 Diamond T, Nery L & Posen S. Spinal and peripheral bone mineral 
densities in acromegaly: the effects of excess growth hormone and 
hypogonadism. *Annals of Internal Medicine* 1989 **111** 567–573. (doi:
7326/0003-4819-11-7-567)


41 Berrymen DE, Christiansen JS, Johannsson G, Thorner MO & 
Kopchick J. Role of the GH/IGF1 axis in lifespan and healthspan: 


43 Berrymen DE, Christiansen JS, Johannsson G, Thorner MO & 
Kopchick J. Role of the GH/IGF1 axis in lifespan and healthspan: 

44 Fernholm R, Brannmert M, Hagg E, Hilding A, Baylink DJ, Mohan S & 
Thörn M. Growth hormone replacement therapy improves body 
composition and increased bone metabolism in elderly patients with 

45 Hoffman AR, Kuntze JE, Baptista J, Baum HB, Baumann GP, Biller BM, 
Clark RV, Cook D, Inzucchi SE & Kleinberg D. Growth hormone (GH) 
replacement therapy in adult-onset GH deficiency. Effects on body 
composition in men and women in a double-blind, randomized, 

46 Kenth G, Shao Z, Cole DE & Goodyer CG. Relationship of the human growth hormone receptor exon 3 genotype with final adult height and 

---

Received 24 December 2013
Revised version received 21 May 2014
Accepted 27 May 2014